{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:55:14Z","timestamp":1760147714835,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Guangdong Province","award":["2018A030313651"],"award-info":[{"award-number":["2018A030313651"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7\u201391.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24\u201374) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR\/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1\u201351.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.<\/jats:p>","DOI":"10.3390\/jpm13030412","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T02:22:16Z","timestamp":1677464536000},"page":"412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6462-3547","authenticated-orcid":false,"given":"Junru","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: An overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_2","first-page":"e16372","article-title":"Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients","volume":"13","author":"Miles","year":"2021","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: A review","volume":"46","author":"Poh","year":"2020","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple Myeloma and Acute Myelomonocytic Leukemia","volume":"283","author":"Kyle","year":"1970","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council\u2019s working party on leukaemia in adults","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: Influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani","year":"2012","journal-title":"Blood"},{"key":"ref_12","first-page":"593","article-title":"Secondary acute lymphoblastic leukaemia in a multiple myeloma patient","volume":"6","author":"Piszcz","year":"2012","journal-title":"Contemp. Oncol. Pozn."},{"key":"ref_13","first-page":"9052314","article-title":"Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features","volume":"2018","author":"Khan","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-15-2242","article-title":"Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein\u2013Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression","volume":"22","author":"Jones","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00277-016-2775-y","article-title":"Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q","volume":"95","author":"Balaian","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: A case series","volume":"35","author":"Tan","year":"2015","journal-title":"Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41375-018-0213-y","article-title":"Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma","volume":"33","author":"Aldoss","year":"2018","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-008-0680-8","article-title":"Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma","volume":"88","author":"Ueda","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.leu.2403587","article-title":"Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma","volume":"19","author":"Lau","year":"2004","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3109\/10428194.2013.786072","article-title":"Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma","volume":"54","author":"Rabasa","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdn182","article-title":"Biologic features and treatment outcome of secondary acute lymphoblastic leukemia\u2014A review of 101 cases","volume":"19","author":"Shivakumar","year":"2008","journal-title":"Ann. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:42:35Z","timestamp":1760121755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jpm13030412"],"URL":"https:\/\/doi.org\/10.3390\/jpm13030412","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2023,2,25]]}}}